Gene Vital for Post-stroke Recovery Identified

Patients with certain variants of the PATJ gene have less ability to recover after suffering a stroke, stated data from an international, multicentre study coordinated by researchers at the Hospital del Mar Medical Research Institute (IMIM) and //doctors from the Hospital del Mar, published in the journal Circulation Research. This is the most important research carried out so far in the field of genetics and stroke prognosis, and the first published: it uses data from more than 2,000 patients and involves 12 centres from around the world. The study was carried out thanks to the help of the 2010 edition of La Marató de TV3.

Dr. Jordi Jiménez Conde, coordinator of the study and attending physician at the Hospital del Mar's Neurology Department, explained that "It is the largest study published to date on the genetics and prognosis of stroke, and the first that has found consistent results and been replicated in different countries."

They analysed the degree of disability after three months of more than 2,000 patients with ischemic stroke --caused by the blockage of a cerebral artery and which represents 88% of total strokes-- by studying multiple clinical factors and genetic data. Specifically, more than 5 million genetic variants were studied for each individual. "The PATJ gene shows several variants that significantly influence recovery in patients", says Dr. Jiménez Conde. It is a gene involved in cell binding that has a strong presence in nervous tissue and which has already been associated with sleep disorders and obesity.

Genetic influence on recovery

"In this study, we identified a set of genetic variants that are relatively common in the population, and which are associated with worse recovery from stroke after three months", stresses Dr. Marina Mola-Caminal, first author of the study and a researcher in the IMIM's Neurovascular Research Group. This leads the way to studying the mechanisms used by the PATJ gene to influence this process. "In the future, these variants could be used as biomarkers for stroke sufferers, and, depending on the presence of risk alleles (alternative forms of a gene) in each individual, rehabilitation strategies could be personalised."

At the same time "we are able to indicate a region of the genome that is heavily involved in neuroplasticity and neuroregeneration processes, and perhaps if we understand the pathways, we will be able develop new treatments that use this gene as a therapeutic target and help improve patient prognosis", notes Dr. Jiménez Conde.

Advertisement

The study also involved Dr. Israel Fernández, co-researcher in the study and participant in its design and coordination. He is currently at the Hospital de la Santa Creu i Sant Pau Research Institute but at the time of the study was part of the Vall d'Hebron Research Institute (VHIR) and Mutua de Terrassa Neurovascular Research Laboratory. Dr. Fernández comments that "All neuroprotective drugs tested to improve post-stroke recovery have failed. For that reason, this study, utilising mass genetic strategies, may be the first step towards developing new drugs that are truly effective."

Source-Eurekalert